Compliance Certifcate under Reg 74 (5) of SEBI (DP) Regulation , 2018
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medicamen Biotech has filed a compliance certificate confirming proper handling of securities dematerialization/rematerialization for Q4 FY2026 (quarter ended March 31, 2026). The company's Registrar, MUFG Intime India Private Limited, certified that physical share certificates received for dematerialization have been mutilated and cancelled after verification, with depositories substituted as registered owners within the 30-day regulatory timeline. This is a routine regulatory filing confirming the company follows SEBI rules for electronic share processing. No material discrepancies or unusual activity were reported.
Routine compliance filing with no direct impact on stock price or shareholder value. Confirms proper regulatory adherence to SEBI's dematerialization rules.